Perseus-Soros Biopharmaceutical Fund - Web3 Crypto Company Profile, Funding, Valuation, Investors - Cointime

Bitcoin $79,688.24 +4.17%
Ethereum $3,207.31 +5.04%
BNB $635.82 +1.52%
Optimism $1.67 +1.11%
Arbitrum $0.64 +4.50%
Solana $205.57 +1.33%
Polygon $0.41 +4.93%
Cosmos $5.27 +10.17%
Avalanche $32.03 +8.51%

Bitcoin $79,688.24 +4.17%
Ethereum $3,207.31 +5.04%
BNB $635.82 +1.52%
Optimism $1.67 +1.11%
Arbitrum $0.64 +4.50%
Solana $205.57 +1.33%
Polygon $0.41 +4.93%
Cosmos $5.27 +10.17%
Avalanche $32.03 +8.51%

Perseus-Soros Biopharmaceutical Fund

investment firm

Summary
Founds Raised
Investments
Exits

About

Perseus-Soros Biopharmaceutical Fund, L.P. specializes in equity investments in private and public life science companies.

New York,New York,United States

Highlights

Lead Investments

Details

Operating Status: Active
Investor Type: PE

Funds Raised

Announced Date	Fund Name		Money Raised
Jan 1, 2000	Perseus-Soros BioPharmaceutical Fund		$449M

Investments

Number of Investments

Number of Lead Investments

22

5

Perseus-Soros Biopharmaceutical Fund has made 22 investments. Their most recent investment was on Oct 30, 2009, when Xanodyne raised $87.78M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Oct 30, 2009 Xanodyne	Series Unknown	$87.78M	Biotechnology	—
Sep 29, 2008 CeNeRx BioPharma	Series B	$15M	Biopharma	—
Nov 14, 2007 Ambit Biosciences	Series D	$49.30M	Biopharma	—
May 1, 2006 Cardiokine	Series B	$50M	Biotechnology	—
Apr 12, 2006 SkinMedica	Series E	$11M	Biotechnology	—

Show More

Exits

Perseus-Soros Biopharmaceutical Fund has had 9 exits. Perseus-Soros Biopharmaceutical Fund most notable exits include Ambit Biosciences , SkinMedica

Date	Company Name	Exit Type	Industry
May 16, 2013	Ambit Biosciences	M&A	Biopharma	Detail
Nov 16, 2012	SkinMedica	M&A	Biotechnology	Detail
Jan 4, 2012	Cardiokine	M&A	Biotechnology	Detail
Oct 26, 2011	Advion Inc.	M&A	Biotechnology	Detail
May 27, 2010	Aton Pharma	M&A	Biotechnology	Detail

Show More